Vermillion Shareholders Seek Change in Board Members | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A trio of Vermillion shareholders have notified the firm that they intend to nominate two people for election to the board of directors as they seek to replace Gail Page and John Hamilton.

Page is Vermillion's president and CEO, and Hamilton is a former VP and CFO of Depomed but is not an executive of the firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.